相关实验视频

Updated: Jan 18, 2026

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy

Published on: January 25, 2019

超越治疗糖尿病黄斑的内膜法里西马布的第一年:单中心体验

Theodore Tsilegeridis-Legeris¹, Nihal Kenawy¹

¹Ophthalmology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, GBR.

|September 8, 2025

概括

内法利西马布 (IVF) 维持了视力稳定性,并在糖尿病黄斑胀 (DMO) 患者的视网膜厚度显著降低,直到第二年. 治疗显示出持久的疗效和安全性,大多数眼睛出现稳定或改善的糖尿病视网膜病变 (DR).

科学领域:

眼科医生眼科眼科
视网膜疾病视网膜疾病
药理疗法药理疗法药理疗法

背景情况:

糖尿病黄斑 (DMO) 是糖尿病患者视力丧失的主要原因.
内抗血管内皮生长因子 (抗VEGF) 药物是标准的DMO治疗方法.
法里西马布是一种新型双特异性抗体,向血管蛋白-2和VEGF-A.

研究的目的:

评估DMO治疗第二年内内法利西马布 (IVF) 的实际临床结果.
评估视力变化,视网膜解剖,糖尿病视网膜病变 (DR) 严重程度和视网膜扩散 (ERP) /视网膜膜 (ERM) 发生率.
确定DMO患者体外受精的安全性和耐久性.

主要方法:

一个单一的中心,对158只眼睛进行了回顾性观察研究,这些眼睛是用DMO接受试管婴儿治疗的.
患者被分为先前未接受过治疗和反VEGF转换组.
分析了包括最佳校正视敏度 (BCVA),中枢视网膜厚度 (CFT),DR严重程度,ERP/ERM发生率和安全性在内的临床结果,平均随访时间为75周.

主要成果:

在原始 (-141μm) 和切换 (-115μm) 组中观察到CFT显著减少 (P < 0.0001).
52周,BCVA的平均值显示了原始眼睛的改善 (+3.6个字母,P=0.04) 和交换眼睛的稳定性 (+1.3个字母,P=0.34).
DR回归或稳定率高 (97%),ERP/ERM发生率中等 (25.6%原始,34.1%切换) 并且没有报告的安全事件.

结论:

内法利西马布在DMO患者中显示出显著的结构改善和耐久性,持续到治疗的第二年.
保持BCVA稳定性,DR严重程度通常会降低或稳定.
法里西马布为DMO提供了一种持久且安全的治疗选择,ERP/ERM的发病率可控.

关键词:

进行反素食治疗.糖尿病性黄斑 (DME) 是一种疾病.糖尿病性黄斑胀糖尿病性黄斑胀法里西马布 (法里西马布) 是一个法里西马布.法里西马布静脉内射注射内抗素抗素fffffffffffff 静脉内注射静脉内注射静脉内注射静脉内注射现实世界的真实世界.现实世界的数据数据.

更多相关视频

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...